Jun 2026 (Q2 FY26) — Aug 21, 2026
ZKH Group Limited Q2 FY26 — First Quarterly Operating Profitability and Accelerated GMV Growth
Read the full callZKH Group earnings: last reported Fri, 21 Aug 2026, for the quarter ended Jun 2026.
Price
1Y: $2.86 on 17 Oct 2025 → $1.86. High $3.79 (29 Dec 2025), low $1.75 (16 Oct 2026).
Overview
Call summaries
ZKH Group Limited Q2 FY26 — First Quarterly Operating Profitability and Accelerated GMV Growth
Read the full callEvery analysed call
Financials
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 |
| Reserves | — | -583 | -691 | -709 | -759 |
| Total liabilities | — | 536 | 588 | 481 | 513 |
| Fixed assets | — | 24 | 20 | 25 | 27 |
| Investments | — | — | 123 | 75 | 118 |
| Total assets | — | 988 | 1,040 | 906 | 933 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash from operations | -218 | -73 | -80 | 31 | 1 |
| Cash from investing | -15 | -5 | -128 | 38 | -46 |
| Cash from financing | 27 | 189 | 101 | -35 | -15 |
| Net cash flow | -206 | 127 | -106 | 37 | -61 |
| Capital expenditure | -23 | -5 | -7 | -11 | -8 |
| Free cash flow | -241 | -78 | -87 | 21 | -6 |
3 filings between Aug 31, 2026 and Sep 11, 2026.
Purchases
None
No insider bought shares.
Sales
$831.6K
2 sales by 1 insider
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Han Yunjie | — | $831.6K | Sep 11, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 11, 2026 | Han Yunjie Director | Sale | 9,289,000 | $774.7K |
| Sep 9, 2026 | Han Yunjie Director | Sale | 672,910 | $56.9K |
| Aug 31, 2026 | Han Yunjie Director | Award | 9,999,990 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow ZKH Group Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading